Elicio Therapeutics' KRAS Cancer Vaccine Misses Phase 2 Primary Endpoint, Stock Plunges Over 74% in Two Days

Economic Observer NetworkElicio Therapeutics, Inc.’s Core KRAS Cancer Vaccine Fails to Meet Primary Endpoint in Phase II Clinical Trial, Stock Plummets, and Fundamental Uncertainty Rises.

Recent Events:

On June 15, the company announced key top-line data from the Phase II study (AMPLIFY-7P) of ELI-002 7P as adjuvant therapy for pancreatic cancer. The results showed that the primary endpoint of disease-free survival (DFS) was not met in the overall population analysis. Although a signal of benefit was observed in a subgroup (R0 resection, accounting for 84%) (median DFS 23.8 months vs. 12.8 months), the negative result in the overall population directly undermines the short-term prospects of the project.. B. Riley analyst Mayank Mamtani pointed out that the subsequent value of the pipeline will depend entirely on validation in the low-residual subgroup population in Phase III trials.。

Recent Stock Performance:

Elicio Therapeutics (ELTX.US) hit a 60-day low on June 16 (closing at $2.76), primarily because its core KRAS cancer vaccine, ELI-002 7P, failed to meet the primary endpoint in pivotal Phase II clinical data, leading to a sharp downward revision of market expectations for the near-term commercialization of its pipeline.. This negative news triggered a market sell-off:

* June 15: The stock price plummeted by 72.53% to $4.08, with trading volume surging to 8.46 million shares.

* June 16: The stock price continued to decline, hitting a low of $2.66 and finally closing at $2.76, a further drop of 32.35%, with trading volume remaining as high as 4.84 million shares. This brings the cumulative decline in its stock price to approximately 74% from $9.57 on May 18.

Company Fundamentals:

This sharp decline has amplified the company’s already fragile fundamental risks: as a clinical-stage company, it generates no revenue (Q1 2026 revenue was zero) and continues to incur losses (Q1 net loss of $11.82 million), with a debt-to-asset ratio as high as 106.33%. Major setbacks in its core pipeline have significantly increased uncertainty surrounding future financing and R&D progress.

The above content is compiled based on publicly available information and does not constitute investment advice.